Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Increased risk for vascul… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.

Artikel i vetenskaplig tidskrift
Författare Peter Johansson
Anne Ricksten
Lovisa Wennström
Lars Palmqvist
Jack Kutti
Björn Andréasson
Publicerad i British journal of haematology
Volym 123
Nummer/häfte 3
Sidor 513-6
ISSN 0007-1048
Publiceringsår 2003
Publicerad vid Institutionen för invärtesmedicin, Avdelningen för internmedicin
Institutionen för laboratoriemedicin, Avdelningen för klinisk kemi/transfusionsmedicin
Sidor 513-6
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Aged, Aged, 80 and over, Female, GPI-Linked Proteins, Humans, Isoantigens, Male, Membrane Glycoproteins, Middle Aged, Platelet Aggregation Inhibitors, therapeutic use, Prognosis, RNA, Messenger, analysis, Receptors, Cell Surface, genetics, Reverse Transcriptase Polymerase Chain Reaction, Risk Factors, Thrombocythemia, Essential, blood, drug therapy, Thromboembolism, drug therapy, genetics
Ämneskategorier Klinisk laboratoriemedicin, Hematologi

Sammanfattning

Essential thrombocythaemia (ET) is a heterogeneous disorder with respect to plasma erythropoietin concentration at diagnosis and clonality of haematopoiesis. Polycythaemia rubra vera-1 (PRV-1) positivity, i.e. PRV-1 mRNA overexpression, is known to be present in the vast majority of patients with polycythaemia vera and also in some patients with ET. In the present study, PRV-1 expression was quantified by real-time polymerase chain reaction in 70 ET patients; 17 of them (24%) were found to be PRV-1 positive. Ten of the 17 PRV-1 positive ET patients had experienced thromboembolic complications compared with 14 of 53 PRV-1 negative patients, the difference between the two groups being statistically significant (P=0.02). In addition, the frequency of total vascular complications, thromboembolic events and major bleedings, was significantly higher in the group of PRV-1 positive as compared with PRV-1 negative ET patients (P=0.03). The time from diagnosis of ET to the requirement of platelet-lowering therapy was significantly shorter in PRV-1 positive compared with PRV-1 negative ET patients (P=0.014). It can be concluded that PRV-1 positive patients appear to suffer from a more aggressive disorder with increased risk for vascular complications and a greater need for platelet-lowering therapy, compared with PRV-1 negative ET patients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?